Natixis Has $5.29 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Natixis boosted its position in United Therapeutics Co. (NASDAQ:UTHR) by 80.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 67,758 shares of the biotechnology company’s stock after buying an additional 30,178 shares during the quarter. Natixis owned approximately 0.15% of United Therapeutics worth $5,289,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the stock. Oak Associates Ltd. OH grew its stake in United Therapeutics by 2.3% in the first quarter. Oak Associates Ltd. OH now owns 4,675 shares of the biotechnology company’s stock valued at $549,000 after purchasing an additional 105 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its stake in United Therapeutics by 1.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,080 shares of the biotechnology company’s stock valued at $631,000 after purchasing an additional 130 shares in the last quarter. Nissay Asset Management Corp Japan ADV grew its stake in United Therapeutics by 2.9% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,029 shares of the biotechnology company’s stock valued at $590,000 after purchasing an additional 144 shares in the last quarter. Permanens Capital L.P. grew its stake in United Therapeutics by 2.5% in the second quarter. Permanens Capital L.P. now owns 6,150 shares of the biotechnology company’s stock valued at $480,000 after purchasing an additional 150 shares in the last quarter. Finally, NEXT Financial Group Inc grew its stake in United Therapeutics by 72.7% in the second quarter. NEXT Financial Group Inc now owns 475 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 200 shares in the last quarter. 94.16% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have weighed in on the company. Zacks Investment Research downgraded United Therapeutics from a “buy” rating to a “hold” rating and set a $86.00 price target for the company. in a research note on Wednesday, August 14th. BidaskClub downgraded United Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Wedbush reiterated a “buy” rating and set a $273.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. ValuEngine upgraded United Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Jefferies Financial Group upgraded United Therapeutics from an “underperform” rating to a “hold” rating and set a $90.00 target price for the company in a research note on Thursday, August 1st. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $120.36.



UTHR traded down $2.73 during trading on Thursday, hitting $80.19. The stock had a trading volume of 127,434 shares, compared to its average volume of 541,395. The company has a 50 day moving average price of $80.73 and a 200-day moving average price of $93.03. The firm has a market cap of $3.64 billion, a price-to-earnings ratio of 5.99 and a beta of 0.92. United Therapeutics Co. has a one year low of $74.31 and a one year high of $129.59. The company has a debt-to-equity ratio of 0.31, a current ratio of 4.62 and a quick ratio of 4.41.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $4.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.40 by $2.26. The business had revenue of $373.60 million during the quarter, compared to the consensus estimate of $331.78 million. United Therapeutics had a negative return on equity of 4.54% and a negative net margin of 7.69%. As a group, sell-side analysts predict that United Therapeutics Co. will post -1.96 EPS for the current fiscal year.

In other United Therapeutics news, Director Raymond Dwek sold 3,750 shares of United Therapeutics stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $76.11, for a total value of $285,412.50. Following the completion of the transaction, the director now directly owns 3,750 shares of the company’s stock, valued at approximately $285,412.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard Giltner sold 5,000 shares of United Therapeutics stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $79.05, for a total value of $395,250.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $395,250. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: What member countries make up the G-20?

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.